Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.64 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.64 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19212992 | 0.86 | CES2 (0.56) | CYP11B1CYP11B2MAOBPTGS2HPGD | |
| SCHEMBL19212944 | 0.83 | HPGD (0.64) | CYP11B1CYP11B2MAOBPTGS2HPGD | |
| SCHEMBL19212996 | 0.82 | CYP11B1 (0.67) | CYP11B1CYP11B2MAOBPTGS2 | |
| SCHEMBL19212971 | 0.82 | CYP11B1 (0.68) | CYP11B1CYP11B2MAOBPTGS2AKR1C3 | |
| SCHEMBL17723869 | 0.79 | CYP11B1 (1.00) | CYP11B1CYP11B2 | |
| SCHEMBL8669129 | 0.79 | CES2 (0.58) | CYP11B1CYP11B2HPGDELANE | |
| SCHEMBL26813754 | 0.78 | CYP11B1 (0.48) | CYP11B1CYP11B2PTGS2AKR1C3AKR1C2 | |
| SCHEMBL19212935 | 0.75 | CYP11B1 (0.64) | CYP11B1CYP11B2HPGDMGLLELANE | |
| SCHEMBL14367111 | 0.75 | CES2 (0.55) | CYP11B1CYP11B2PTGS2AKR1C3 | |
| SCHEMBL7814053 | 0.74 | MAOB (0.63) | MAOBPTGS2AKR1C3AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790217-B2 | Pyridinyloxy- and phenyloxy-pyrazolyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170226097-A1 | PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226097-A1 | PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | PDXK, PNPO, PAH | CYP11B1 84/4885CYP11B2 32/4885MAOB 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.